PMID- 27754828 OWN - NLM STAT- MEDLINE DCOM- 20170215 LR - 20181113 IS - 1840-4812 (Electronic) IS - 1512-8601 (Print) IS - 1512-8601 (Linking) VI - 16 IP - 4 DP - 2016 Nov 10 TI - Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study. PG - 268-275 LID - 10.17305/bjbms.2016.1568 [doi] AB - Multiple myeloma (MM) is a malignancy of B lymphocytes or plasma cells. Our array-based comparative genomic hybridization findings revealed chromosomal gains at 7q22.3 and 1q42.3, where nicotinamide (NAM) phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) genes are localized, respectively. This led us to further study the functions of these genes in myeloma cells. NAMPT is a key enzyme involved in nicotinamide adenine dinucleotide salvage pathway, and it is frequently overexpressed in human cancers. In contrast, little is known about the function of LYST in cancer. The expression of LYST is shown to affect lysosomal size, granule size, and autophagy in human cells. In this study, the effects of small interfering RNA (siRNA)-mediated silencing of NAMPT and LYST on cell proliferation and apoptosis were evaluated in RPMI 8226 myeloma cells. Transfection efficiencies were determined by quantitative real time reverse transcriptase PCR. Cell proliferation was determined using MTT assay, while apoptosis was analyzed with flow cytometry using Annexin V-fluorescein isothiocyanate/propidium iodide assay. The NAMPT protein expression in siRNA-treated cells was estimated by enzyme-linked immunosorbent assay. Our results showed that NAMPT and LYST were successfully knockdown by siRNA transfection (p < 0.05). NAMPT or LYST gene silencing significantly inhibited cell proliferation and induced apoptosis in RPMI 8226 cells (p < 0.05). Silencing of NAMPT gene also decreased NAMPT protein levels (p < 0.01). Our study demonstrated that NAMPT and LYST play pivotal roles in the molecular pathogenesis of MM. This is the first report describing the possible functions of LYST in myelomagenesis and its potential role as a therapeutic target in MM. FAU - Bong, Ivyna Pau Ni AU - Bong IP AD - Haematology Unit, Cancer Research Centre, Institute for Medical Research, Kuala Lumpur, Malaysia; Department of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia. ivyna@imr.gov.my. FAU - Ng, Ching Ching AU - Ng CC FAU - Fakiruddin, Shaik Kamal AU - Fakiruddin SK FAU - Lim, Moon Nian AU - Lim MN FAU - Zakaria, Zubaidah AU - Zakaria Z LA - eng PT - Journal Article DEP - 20161110 PL - Bosnia and Herzegovina TA - Bosn J Basic Med Sci JT - Bosnian journal of basic medical sciences JID - 101200947 RN - 0 (Cytokines) RN - 0 (LYST protein, human) RN - 0 (Neoplasm Proteins) RN - 0 (RNA, Small Interfering) RN - 0 (Vesicular Transport Proteins) RN - EC 2.4.2.12 (Nicotinamide Phosphoribosyltransferase) RN - EC 2.4.2.12 (nicotinamide phosphoribosyltransferase, human) SB - IM MH - Apoptosis/*drug effects MH - Cell Line, Tumor MH - Cell Proliferation MH - Cytokines/*genetics MH - Gene Knockdown Techniques MH - *Gene Silencing MH - Genetic Therapy MH - Humans MH - Multiple Myeloma/*genetics/*therapy MH - Neoplasm Proteins/biosynthesis MH - Nicotinamide Phosphoribosyltransferase/*genetics MH - RNA, Small Interfering/*pharmacology MH - Vesicular Transport Proteins/*genetics PMC - PMC5136762 EDAT- 2016/10/19 06:00 MHDA- 2017/02/16 06:00 PMCR- 2016/11/01 CRDT- 2016/10/19 06:00 PHST- 2016/07/28 00:00 [received] PHST- 2016/08/20 00:00 [accepted] PHST- 2016/08/18 00:00 [revised] PHST- 2016/10/19 06:00 [pubmed] PHST- 2017/02/16 06:00 [medline] PHST- 2016/10/19 06:00 [entrez] PHST- 2016/11/01 00:00 [pmc-release] AID - BJBMS-16-268 [pii] AID - 10.17305/bjbms.2016.1568 [doi] PST - epublish SO - Bosn J Basic Med Sci. 2016 Nov 10;16(4):268-275. doi: 10.17305/bjbms.2016.1568.